192 related articles for article (PubMed ID: 37259866)
1. New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing.
Oostveen RF; Khera AV; Kathiresan S; Stroes ESG; Fitzgerald K; Harms MJ; Oakes BL; Kastelein JJP
Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):1081-1092. PubMed ID: 37259866
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting
Lee RG; Mazzola AM; Braun MC; Platt C; Vafai SB; Kathiresan S; Rohde E; Bellinger AM; Khera AV
Circulation; 2023 Jan; 147(3):242-253. PubMed ID: 36314243
[TBL] [Abstract][Full Text] [Related]
3.
Wagner J; Bell AS; Lohoff FW
ACS Chem Neurosci; 2022 Dec; 13(23):3210-3212. PubMed ID: 36374568
[TBL] [Abstract][Full Text] [Related]
4. Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries.
Nishikido T; Ray KK
Front Cardiovasc Med; 2018; 5():199. PubMed ID: 30761308
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.
Chadwick AC; Wang X; Musunuru K
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1741-1747. PubMed ID: 28751571
[TBL] [Abstract][Full Text] [Related]
6. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
Sinning D; Landmesser U
Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
[TBL] [Abstract][Full Text] [Related]
7. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease.
Nishikido T
Cardiovasc Diabetol; 2023 Jan; 22(1):20. PubMed ID: 36717882
[TBL] [Abstract][Full Text] [Related]
8. Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus.
Rakocevic J; Dobric M; Vucic R; Furtula M; Zaletel I; Milutinovic K; Ilijevski A; Borovic ML; Tomasevic M; Bajcetic M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983086
[TBL] [Abstract][Full Text] [Related]
9. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies.
Brandts J; Ray KK
Curr Opin Lipidol; 2020 Aug; 31(4):182-186. PubMed ID: 32487819
[TBL] [Abstract][Full Text] [Related]
10. Gene Editing for the Treatment of Hypercholesterolemia.
Hoekstra M; Van Eck M
Curr Atheroscler Rep; 2024 May; 26(5):139-146. PubMed ID: 38498115
[TBL] [Abstract][Full Text] [Related]
11. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing.
Chadwick AC; Musunuru K
Curr Atheroscler Rep; 2017 Jul; 19(7):32. PubMed ID: 28550381
[TBL] [Abstract][Full Text] [Related]
13. Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.
He NY; Li Q; Wu CY; Ren Z; Gao Y; Pan LH; Wang MM; Wen HY; Jiang ZS; Tang ZH; Liu LS
Acta Pharmacol Sin; 2017 Mar; 38(3):301-311. PubMed ID: 28112180
[TBL] [Abstract][Full Text] [Related]
14. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.
Carreras A; Pane LS; Nitsch R; Madeyski-Bengtson K; Porritt M; Akcakaya P; Taheri-Ghahfarokhi A; Ericson E; Bjursell M; Perez-Alcazar M; Seeliger F; Althage M; Knöll R; Hicks R; Mayr LM; Perkins R; Lindén D; Borén J; Bohlooly-Y M; Maresca M
BMC Biol; 2019 Jan; 17(1):4. PubMed ID: 30646909
[TBL] [Abstract][Full Text] [Related]
15. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
16. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
Warden BA; Duell PB
J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.
Wang X; Raghavan A; Chen T; Qiao L; Zhang Y; Ding Q; Musunuru K
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):783-6. PubMed ID: 26941020
[TBL] [Abstract][Full Text] [Related]
18. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
19. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
20. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]